RhumbLine Advisers’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-82,708
| Closed | -$1.3M | – | 4390 |
|
|
2024
Q1 | $1.3M | Buy |
82,708
+1,923
| +2% | +$29.6K | ﹤0.01% | 2110 |
|
|
2023
Q4 | $1.3M | Sell |
80,785
-10
| -0% | -$128 | ﹤0.01% | 2128 |
|
|
2023
Q3 | $1.03M | Buy |
80,795
+459
| +0.6% | +$6.33K | ﹤0.01% | 2193 |
|
|
2023
Q2 | $1.13M | Buy |
80,336
+3,080
| +4% | +$44.1K | ﹤0.01% | 2222 |
|
|
2023
Q1 | $1.19M | Buy |
77,256
+9,830
| +15% | +$164K | ﹤0.01% | 2046 |
|
|
2022
Q4 | $1.1M | Buy |
67,426
+2,070
| +3% | +$33.7K | ﹤0.01% | 2075 |
|
|
2022
Q3 | $1.21M | Buy |
65,356
+4,688
| +8% | +$73.6K | ﹤0.01% | 2038 |
|
|
2022
Q2 | $798K | Buy |
60,668
+16,986
| +39% | +$187K | ﹤0.01% | 2250 |
|
|
2022
Q1 | $405K | Buy |
43,682
+414
| +1% | +$3.52K | ﹤0.01% | 2514 |
|
|
2021
Q4 | $423K | Sell |
43,268
-1,035
| -2% | -$19.5K | ﹤0.01% | 2579 |
|
|
2021
Q3 | $1.5M | Buy |
44,303
+1,227
| +3% | +$39.2K | ﹤0.01% | 2040 |
|
|
2021
Q2 | $1.58M | Sell |
43,076
-678
| -2% | -$26.3K | ﹤0.01% | 2057 |
|
|
2021
Q1 | $1.96M | Sell |
43,754
-3,835
| -8% | -$179K | ﹤0.01% | 1924 |
|
|
2020
Q4 | $2.72M | Buy |
47,589
+841
| +2% | +$49.9K | ﹤0.01% | 1695 |
|
|
2020
Q3 | $2.4M | Sell |
46,748
-10,560
| -18% | -$517K | ﹤0.01% | 1570 |
|
|
2020
Q2 | $3.42M | Buy |
57,308
+28,507
| +99% | +$1.52M | 0.01% | 1427 |
|
|
2020
Q1 | $1.19M | Buy |
28,801
+2,569
| +10% | +$143K | ﹤0.01% | 1802 |
|
|
2019
Q4 | $1.63M | Buy |
26,232
+3,739
| +17% | +$178K | ﹤0.01% | 1873 |
|
|
2019
Q3 | $763K | Buy |
22,493
+6,245
| +38% | +$185K | ﹤0.01% | 2158 |
|
|
2019
Q2 | $366K | Buy |
16,248
+4,907
| +43% | +$115K | ﹤0.01% | 2501 |
|
|
2019
Q1 | $263K | Sell |
11,341
-125
| -1% | -$3.27K | ﹤0.01% | 2611 |
|
|
2018
Q4 | $241K | Buy |
11,466
+4,000
| +54% | +$98.3K | ﹤0.01% | 2643 |
|
|
2018
Q3 | $289K | Sell |
7,466
-175
| -2% | -$6.47K | ﹤0.01% | 2537 |
|
|
2018
Q2 | $301K | Buy |
+7,641
| New | +$225K | ﹤0.01% | 2532 |
|
Other funds holding DCPH
RhumbLine Advisers's DCPH Position: Q2 2024 in Review
RhumbLine Advisers sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 82,708 shares — an estimated $1.3M sold.
RhumbLine Advisers first reported a position in DCPH in Q2 2018 and held it in 24 quarters. The position peaked at $3.42M in Q2 2020. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.
- RhumbLine Advisers reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- RhumbLine Advisers sold 82,708 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $1.3M.
- RhumbLine Advisers first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 24 quarters.
- RhumbLine Advisers's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $3.42M in Q2 2020.
- 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on RhumbLine Advisers's 13F filing for Q2 2024, filed 1 Aug 2024.